TG

Tredegar Corporation 10-K Summary (Fiscal Year Ended Dec 31, 2001)

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2001. Tredegar Corporation operates through four primary segments: Film Products (plastic films for hygiene and packaging), Aluminum Extrusions (soft alloy extrusions for construction and transportation), Tredegar Biotech (healthcare technologies via subsidiaries Therics and Molecumetics), and Tredegar Investments (venture capital). The company is headquartered in Richmond, Virginia, and employs approximately 3,200 people.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 12% to $767.6 million, primarily driven by a 20% volume decline in the Aluminum Extrusions segment due to adverse economic conditions and cyclical downturns in end-use markets. Film Products sales remained relatively flat ($382.7 million vs. $380.2 million) despite a 3% volume decline, offset by higher-value product sales and growth in Europe and China.
• Profitability Collapse: Net income plummeted from $111.4 million in 2000 to $9.8 million in 2001. This was largely due to a reversal in the Tredegar Investments segment, which swung from a $130.9 million gain in 2000 to a $26.0 million loss in 2001 due to market volatility and write-downs in the venture capital portfolio.
• Unusual Items: The company recorded $16.0 million in net unusual charges in 2001, including plant shutdowns in El Campo, Texas (Aluminum) and Tacoma, Washington (Film), as well as impairment charges in Argentina.
• Biotech Losses: Operating losses in the Tredegar Biotech segment increased to $21.7 million from $13.6 million due to increased R&D spending at Therics and Molecumetics.

Guidance, Outlook, Risks, and Unusual Items

• Management Commentary: Management noted that while manufacturing businesses generate positive cash flow, the biotech and investment segments carry high risk. The company is rationalizing capacity in both Film and Aluminum segments to align with lower demand.
• Customer Concentration Risk: The Procter & Gamble Company (P&G) accounted for 31% of net sales in 2001. The loss or significant reduction of sales to P&G would have a material adverse effect on the business.
• Market Risks: The company faces exposure to aluminum and resin price volatility, foreign currency fluctuations, and the illiquidity of its venture capital portfolio. The venture capital portfolio's Net Asset Value (NAV) depreciated by $136.7 million in 2001.
• Unusual Items Detail: Significant charges included $7.8 million for the shutdown of the El Campo aluminum plant, $3.0 million for the Tacoma film facility shutdown, and $1.4 million for impairment of the Argentina film business.
• Accounting Changes: The company anticipates adopting new accounting standards in Q1 2002 that will eliminate goodwill amortization, potentially reducing annual amortization expense by approximately $4.6 million.

Investor Verification Checklist

• P&G Dependency: Verify the stability of the relationship with P&G, which represents nearly one-third of total revenue.
• Venture Capital Valuation: Review the methodology for valuing the private venture capital portfolio, which saw a significant drop in fair value and contributed heavily to the earnings decline.
• Biotech Viability: Assess the timeline and funding requirements for Therics and Molecumetics, which have no licensed products and continue to generate operating losses.
• Debt Covenants: Confirm compliance with debt covenants, specifically the 60% debt-to-total capitalization ratio, given the reduction in earnings.
• Plant Rationalization: Monitor the execution and cost savings associated with the planned shutdowns of facilities in Texas, Washington, and Pennsylvania.